



**UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

CS

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/596,196 06/17/00 HALEY

D HYS-14

EXAMINER

HM12/0910

PETRINA S HSI
HYSEQ INC
670 ALMANOR AVENUE
SUNNYVALE CA 94086

SCHNITZER, H

ART UNIT

PAPER NUMBER

1653

DATE MAILED:

09/10/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

FILE COPY

Office Action Summary

Application No.
09/596,196

Applicant(s)
HALEY ET AL.

Examiner
Holly Schnizer

Art Unit
1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 6-17-00.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-30 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-30 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-9, 19, 21-23, and 27-29, drawn to polynucleotides, vectors, host cells, and method of making the polypeptide, classified in class 435, subclass 69.1.
 - II. Claims 10-11, 20, 25, 26, and 30, drawn to a polypeptide and kit comprising the polypeptide, classified in class 530, subclass 350.
 - III. Claim 12, drawn to an antibody, classified in class 530, subclass 387.1.
 - IV. Claims 13-15, drawn to a hybridization assay, classified in class 435, subclass 6.
 - V. Claims 16-18, drawn to a protein binding assay, classified in class 435, subclass 7.1.
 - VI. Claim 24, drawn to a method of treatment comprising administering one of the polypeptides of the invention, classified in class 514, subclass 2.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I-III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, Inventions I-III are independent and distinct, each from the other,

Art Unit: 1653

because they are products that possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention and cannot be exchanged. For example, the polynucleotide may be used as a hybridization probe which is a method that does not require the polypeptide or antibodies of Inventions II and III. Likewise, the polypeptide of Invention II may be used in protein binding or protein purification assays which do not require the polynucleotides or antibodies of Inventions I and III. In addition, the antibodies of Invention III may be used in therapeutic or diagnostic methods that do not require the polynucleotides or polypeptides of Inventions I and II.

3. The methods of Inventions IV-VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of the different Inventions represent different inventive endeavors. Inventions IV-VIII represent separate and distinct methods with different starting materials, method steps, and endpoints; and are used to accomplish separate and distinct goals.

4. Inventions I and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the polynucleotides may be used to make the polypeptide of Group II which is a materially

Art Unit: 1653

different process than the process of detecting a polynucleotide by hybridization of Invention IV.

5. Invention I is unrelated to Inventions V and VI. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the polynucleotides of Invention I are not used in or made by the protein binding method of Invention V or the method of treatment using a polypeptide of Invention VI.

6. Invention II is related to Inventions V and VI as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the polypeptide may be used in a method of making an antibody or as a probe in a method of diagnosis which are materially different processes from the protein binding assays of Invention V and the method of treatment of Invention VI.

7. Inventions II is unrelated to Invention IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the polypeptides of Invention II are not made by or used in the nucleic acid hybridization assays of Invention IV.

Art Unit: 1653

8. Inventions III is unrelated to Inventions IV-VI. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the antibodies of Invention III are not made by or used in the methods of Inventions IV-VI.

Additional Restriction to a Single Polynucleotide, Polypeptide, or Antibody

1. The claims of Groups I-VI are drawn to a multitude of polynucleotides (SEQ ID NOs: 2 and 3), polypeptides (SEQ ID NOs: 4-9), antibodies thereto, and methods of using these compounds. This constitutes a recitation of an implied, mis-joined Markush group that contains multiple, independent and distinct inventions. Each of the different polynucleotides/polypeptides/antibodies and methods of use are independent and distinct because no common structural or functional properties are shared. Accordingly, these claims are subject to restriction under 35 U.S.C. § 121.

2. Upon election of one of Groups I-VI, Applicant is required additionally to elect a single polynucleotide, polypeptide, or antibody (depending on the inventive Group which is elected and including the method groups). This requirement is not to be construed as a requirement for an election of species, since each of the compounds recited in alternative form is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Art Unit: 1653

3. Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, the initial requirement of restriction for examination purposes as indicated is proper.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Holly Schnizer whose telephone number is (703) 305-3722. The examiner can normally be reached on Mon. & Thurs., 8am-5:30pm and Tues. & Wed. 9am-2:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (703) 308-2923. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

HS
Holly Schnizer
September 6, 2001

Christopher S. F. Low
CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600